PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.66%
Revenue growth under 50% of MRVL's 11.85%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
8.42%
Gross profit growth at 75-90% of MRVL's 11.00%. Bill Ackman would demand operational improvements to match competitor gains.
12.38%
EBIT growth below 50% of MRVL's 31.41%. Michael Burry would suspect deeper competitive or cost structure issues.
12.38%
Operating income growth under 50% of MRVL's 31.41%. Michael Burry would be concerned about deeper cost or sales issues.
12.09%
Net income growth under 50% of MRVL's 31.00%. Michael Burry would suspect the firm is falling well behind a key competitor.
8.62%
EPS growth under 50% of MRVL's 39.13%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
14.55%
Diluted EPS growth under 50% of MRVL's 40.91%. Michael Burry would worry about an eroding competitive position or excessive dilution.
1.10%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.07%
Slight or no buyback while MRVL is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-52.37%
Negative OCF growth while MRVL is at 48.70%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-58.37%
Negative FCF growth while MRVL is at 49.74%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
176.31%
10Y revenue/share CAGR under 50% of MRVL's 877.27%. Michael Burry would suspect a lasting competitive disadvantage.
29.17%
5Y revenue/share CAGR at 50-75% of MRVL's 50.62%. Martin Whitman would worry about a lagging mid-term growth trajectory.
5.18%
3Y revenue/share CAGR at 75-90% of MRVL's 6.23%. Bill Ackman would expect new product strategies to close the gap.
-0.16%
Negative 10Y OCF/share CAGR while MRVL stands at 2315.05%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
321.47%
5Y OCF/share CAGR above 1.5x MRVL's 50.73%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-6.42%
Negative 3Y OCF/share CAGR while MRVL stands at 43.64%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
219.36%
Similar net income/share CAGR to MRVL's 236.71%. Walter Schloss would see parallel tailwinds or expansions for both firms.
52.64%
Below 50% of MRVL's 312.91%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
215.77%
3Y net income/share CAGR 1.25-1.5x MRVL's 168.85%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
394.74%
10Y equity/share CAGR above 1.5x MRVL's 73.49%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
94.82%
5Y equity/share CAGR above 1.5x MRVL's 48.49%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
27.97%
3Y equity/share CAGR at 75-90% of MRVL's 35.23%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.36%
Our AR growth while MRVL is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-5.00%
Inventory is declining while MRVL stands at 7.66%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.73%
Asset growth above 1.5x MRVL's 2.39%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.85%
75-90% of MRVL's 7.63%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
-2.02%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
7.00%
R&D growth drastically higher vs. MRVL's 2.91%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
5.52%
SG&A growth well above MRVL's 1.72%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.